Hospital Management
RSSArticles
-
Auth Requirements Are Relaxed During COVID-19 Crisis — Or Are They?
Relaxed authorization requirements sounds like great news. However, payers are vague on the specifics. For this reason, some patient access leaders are erring on the side of caution and continuing to secure all authorizations per usual protocol.
-
‘Top-to-Top’ Approach Needed on Relaxed Rules
Many health plans are waiving authorizations for specific diagnostic testing or services. Clarity is needed on what exactly the waivers mean in specific cases.
-
Waived Cost-Sharing Is Questionable Help to Hospitals
Hospitals may not charge patients with any type of insurance cost-sharing for COVID-19 testing and related services, according to the Families First Coronavirus Response Act. This will certainly help patients. For hospitals, it probably means more lost revenue.
-
CARES Act Offers Mix of Relief, Confusion for Struggling Hospitals
A $100 billion injection of relief funding for certain hospitals and other healthcare providers is just what the doctor ordered. However, for others, the money they will receive does not come close to addressing the shortfalls they are experiencing.
-
Researchers Identify Ethical Concerns with Pragmatic Trials
Pragmatic trials raise some new ethical issues that need greater attention, according to the authors of a recent study.
-
Unique Ethical Concerns for Study Participants in Neuroscience Research
Innovative neuroscience research is vital, but individuals with mental illness pose some unique ethical concerns in terms of their participation. The results of a recent study provided some reassurance on the decision-making processes of individuals.
-
Shortcuts in Clinical Trials May Cause More Harm Than Good
Dozens of potential treatments for COVID-19 are under investigation: existing antiretrovirals, anti-malaria drugs, monoclonal antibodies, and Chinese traditional medicines among them. Additionally, companies are rapidly developing new drugs. But poorly designed studies subject patients to the risks of adverse events without learning if the intervention works.
-
Second Phase of Pandemic Raises More Questions, Concerns for IRBs
Research organizations and IRBs continue to face challenges and make tough decisions based on the best available information about a pandemic that changes daily as it spreads across the world.
-
FDA Guidance Offers Foundation for IRB, Researcher Flexibility
The Food and Drug Administration’s guidance on conducting clinical trials during the pandemic provides reassurance that IRBs and research organizations can employ flexibility as they make changes to accommodate a world in which many patient visits are conducted remotely. The guidance does not change or modify existing regulations, but synthesizes existing regulations and emphasizes the built-in flexibility.
-
What Happens to Human Research in the New Pandemic Era?
The big question in the clinical research world is how things will look when the COVID-19 pandemic has ended. Will everything go back to the way it was? If not, what changes will remain?